Evommune, Inc.
NYSE:EVMN · New York Stock Exchange
-$0.17 today
Vol 0.48M · Avg 0.38M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $48.3M |
| Short-term Investments | $163.1M |
| Other Current | $4.4M |
| Total Current Assets | $215.9M |
| PP&E (Net) | $9.6M |
| Goodwill | $818.1K |
| Intangible Assets | $1.4M |
| Long-term Investments | $97.0M |
| Other Non-current | -$2.1M |
| Total Non-current Assets | $106.6M |
| Total Assets | $322.5M |
Analysis
Selected assets total $322.5M for Latest. The largest visible component is Short-term Investments at $163.1M, about 50.6% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.1M +171.1% | $16.3M -44.0% | $29.0M | $1.3B | $1.2B | $1.0B |
| Short-term Investments | $105.1M +88.5% | $55.8M +11.4% | $50.1M | $1.4B | -$1.7B | -$1.6B |
| Net Receivables | $0 | $0 | $0 | $802.6M | $668.2M | $533.8M |
| Inventory | $0 | $0 | $0 | $664.0M | $652.8M | $641.6M |
| Other Current Assets | $4.3M +119.6% | $1.9M +105.5% | $948.0K | $776.0M | -$1.7B | $1.5B |
| Total Current Assets | $153.5M +107.4% | $74.0M -7.6% | $80.0M | $5.6B | $3.6B | $12.5B |
| Property, Plant & Equipment (Net) | $2.5M +37.0% | $1.8M -8.5% | $2.0M | $1.4B | $575.8M | $1.2B |
| Goodwill | $0 | $0 | $0 | -$1.5B | $1.4B | $925.8M |
| Intangible Assets | $0 | $0 | $0 | $1.1B | $1.4B | $568.8M |
| Long-term Investments | $68.9M +33026.9% | $208.0K +0.0% | $208.0K | $490.4M | $1.2B | $524.0M |
| Tax Assets | $0 | $0 | $0 | $375.6M | $364.4M | $1.5B |
| Other Non-current Assets | $101.0K +65.6% | $61.0K +38.6% | $44.0K | $365.8M | $1.4B | $1.4B |
| Total Non-current Assets | $71.5M +3357.6% | $2.1M -6.8% | $2.2M | $5.2B | $4.7B | -$15.3B |
| Total Assets | $224.9M +195.8% | $76.1M -7.5% | $82.2M | -$16.0B | $14.6B | $13.3B |
| Account Payables | $7.8M -6.1% | $8.3M +370.1% | $1.8M | $991.6M | $1.2B | $1.3B |
| Short-term Debt | $589.0K -42.1% | $1.0M +32.4% | $769.0K | $1.1B | $1.2B | -$1.6B |
| Tax Payables | $0 | $0 | $0 | $843.2M | $708.8M | $574.4M |
| Deferred Revenue | $0 -100.0% | $3.0M | $0 | -$1.6B | $340.6M | -$1.6B |
| Other Current Liabilities | $4.6M -61.6% | $12.1M +539.0% | $1.9M | $1.3B | $650.0M | $1.1B |
| Total Current Liabilities | $17.9M -36.0% | $28.0M +308.1% | $6.9M | $8.7B | $12.8B | $6.0B |
| Long-term Debt | $0 -100.0% | $191.8M +28.4% | $149.4M | $1.1B | $483.4M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $1.3B | $1.2B | $746.6M |
| Deferred Revenue (Non-current) | $0 | $0 -100.0% | $3.0M | $503.0M | $1.0B | -$1.6B |
| Other Non-current Liabilities | $0 -100.0% | $16.0K -93.5% | $245.0K | $869.8M | $1.2B | $489.0M |
| Total Non-current Liabilities | $1.5M -99.2% | $192.3M +25.6% | $153.1M | $4.7B | $11.3B | $3.9B |
| Total Liabilities | $19.4M -91.2% | $220.3M +37.7% | $160.0M | $5.9B | $8.8B | $14.7B |
| Common Stock | $3.0K +200.0% | $1.0K +0.0% | $1.0K | $920.2M | $785.8M | $651.4M |
| Retained Earnings | -$221.1M -45.2% | -$152.2M -81.4% | -$83.9M | $743.8M | $1.0B | -$1.6B |
| Accumulated OCI | $0 | $0 | $0 | $1.5B | -$1.6B | $393.8M |
| Other Stockholders Equity | $0 | $0 | $0 | $620.6M | $486.2M | $351.8M |
| Minority Interest | $0 | $0 | $0 | -$1.7B | $853.0M | $1.4B |
| Total Equity | $205.6M +242.5% | -$144.2M -85.6% | -$77.7M | $11.8B | $10.4B | $9.1B |
| Total Debt | $2.1M -98.9% | $193.3M +28.3% | $150.6M | $746.6M | $735.4M | $724.2M |
| Net Debt | -$42.0M -123.7% | $177.1M +45.6% | $121.6M | $468.0M | -$1.7B | $389.6M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.46B
Galapagos N.V.
GLPG
$1.84B
Zymeworks Inc.
NASDAQ:ZYME
$1.69B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Climb Bio, Inc.
NASDAQ:CLYM
$779.01M
OmniAb, Inc.
NASDAQ:OABI
$262.00M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$238.63M
Codexis, Inc.
NASDAQ:CDXS
$225.88M
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$209.63M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does EVMN have?
Evommune, Inc. (EVMN) reported $44.06M in cash and equivalents in fiscal 2025.
How much debt does EVMN carry?
Evommune, Inc. (EVMN) reported $2.06M of total debt, with net debt of -$42,003,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.